

**Table 1 Summary of patient demographic and clinical characteristics for subgroups 1 and 2**

	Subgroup 1			Subgroup 2		
	PD	Control	P	PD	Control	P
Sample size	10	10		10	10	
Age	67.04 ± 5.35	74.15 ± 7.90	0.03	62.23 ± 2.46	69.37 ± 7.85	0.065
% Female	40%	50%	0.739	40%	70%	0.366
Disease duration (years)	1.10 ± 1.54			2.75 ± 2.46		
MoCA score	26.80 ± 1.87			25.5 ± 3.24		
Number of patients satisfying criteria for PD-MCI (MoCA <26)	2			4		
MDS-UPDRS Total	43.7 ± 15.56			54.5 ± 20.25		
MDS-UPDRS-III	28 ± 10.75			29.90 ± 12.20		
L-Dopa Equivalent dose	290 ± 301.66			324.10 ± 145.16		
Hoehn & Yahr ≤2	90%			90%		
Hoehn & Yahr =3	10%			10%		

**Table 2 Tests for correlation between patient demographic and clinical scores and measures of αS/Aβ ratio, proportion of Aβ aggregates meeting morphology thresholds (threshold Aβ), and the combined discriminator.**

	Combined PD and Control Subgroup Data								
	Ratio			Threshold Aβ			Combined Discriminator		
	cor	Stat (Kendall)	P	cor	Stat (Kendall)	P	cor	Stat (Kendall)	P
Age (years)	-0.250	291	0.021	-0.059	280	0.632	-0.320	202	0.006
	<b>Controls Only</b>								
	cor	Stat (Kendall)	P	cor	Stat (Kendall)	P	cor	Stat (Kendall)	P
Age (years)	-0.032	92	0.873	0.085	83	0.654	-0.190	55	0.308
	<b>PD Only</b>								
	cor	Stat (Kendall)	P	cor	Stat (Pearson)	P	cor	Stat (Kendall)	P
Age (years)	-0.260	70	0.113	0.004	0.017	0.987	-0.2	61	0.260
MDS-UPDRSIII	-0.048	-0.292	0.770	0.018	0.074	0.942	0.026	0.152	0.879
MDS_UPDRS Total	-0.005	-0.0325	0.974	0.16	0.656	0.521	0.15	0.782	0.383
Total ACE-III	0.24	1.454	0.146	-0.085	-0.340	0.736	0.18	0.999	0.318
Total MoCA	0.12	0.692	0.489	0.21	0.862	0.402	0.17	0.961	0.336